54 results
6-K
EX-99.7
AMYT
Amryt Pharma Plc
3 Nov 22
Current report (foreign)
7:44am
on a constant currency basis during Q3 would have been 13.8% YoY.
EMEA growth drivers include reimbursement for partial lipodystrophy (PL) in Italy … , general lipodystrophy (GL) in the Netherlands and a strong performance in Turkey and the Middle East
Reimbursement processes are also being progressed
6-K
EX-99.1
AMYT
Amryt Pharma Plc
3 Nov 22
Current report (foreign)
7:44am
EXHIBIT 99.1
Amryt Receives Reimbursement Approval from the Dutch Ministry of Health for Myalepta® (metreleptin)
DUBLIN, Ireland, and Boston MA … novel treatments for rare diseases, announces that the Dutch Ministry of Health has approved Myalepta® (metreleptin) for reimbursement in the Netherlands
6-K
EX-99.5
AMYT
Amryt Pharma Plc
4 Aug 22
Results of Annual General Meeting
7:38am
general and partial lipodystrophy (GL/PL)
Growth drivers include Italian PL reimbursement in Q2 and expansion in the Middle East and Turkey
Metreleptin
424B3
3sknzuki r7r9j
9 Mar 22
Prospectus supplement
9:26am
424B3
elbtxg
9 Mar 22
Prospectus supplement
9:25am
6-K
EX-99.1
ksw9o0nrh2fubzl
9 Mar 22
Amryt Announces 22% growth in FY 2021 Revenues to $222.5M
9:23am
6-K
EX-99.1
5cdp0wc7l
25 Feb 22
Current report (foreign)
4:05pm
424B3
h7bzf3a4i
1 Jul 21
Prospectus supplement
5:20pm
F-4/A
5d44peto
29 Jun 21
Registration of securities (foreign) (amended)
9:29am
F-4
85lluiqr
15 Jun 21
Registration of securities (foreign)
12:00am
424B3
f6bfh2b
2 Jun 21
Prospectus supplement
10:10am
424B3
m68 81e5xgs
2 Jun 21
Prospectus supplement
10:09am
424B3
l8x02mw
2 Jun 21
Prospectus supplement
10:08am
425
hr12tda skbuxj5n11gz
5 May 21
Business combination disclosure
5:27pm
6-K
EX-99.1
bdbej uvriprn82oq
5 May 21
Amryt Reports Record Q1 2021 Financial and Operating Results
9:40am